Table 1

Short- and long-acting GLP-1 receptor agonists

Short-acting <24 hLong-acting ≥24 h
Twice dailyOnce dailyOnce weekly
Exenatide (launched)Liraglutide (launched)Exenatide LAR (phase 3)
Taspoglutide (phase 3)
Albiglutide (phase 3)
LY2189265 (phase 2)